SOPHiA GENETICS Q2 Earnings Today: The Numbers That Decide the Turnaround Thesis

The filing on your news feed says SOPHiA GENETICS (SOPH) is updating investors with its Form 6-K. That's boilerplate for a Swiss company reporting quarterly results to the SEC. The actual question is whether Q2 2026 gives the stock a new trajectory or confirms it's still a growth story chasing profitability that's further out than management wants you to believe.

The numbers drop before market open today. Here's the framework for reading them.

What the guidance bar is

SOPHiA guided full-year 2026 revenue to $92–94 million, or 20–22% growth over FY2025's $77.3 million. Q1 delivered $21.7 million, which puts 67–72% of the full-year target on the remaining three quarters. Mathematically, that requires roughly $23–24 million per quarter through year-end. If Q2 meets or beats that threshold, the company is on a flat-to-improving run-rate path. If it falls short, the back-half ramp needs to be steeper than the guidance language suggests.

On the profitability side, the company is guiding to an adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization - a rough cash-earnings proxy) loss of $29–32 million. Q1 lost $9.2 million on that measure. That leaves $19.8–22.8 million of runway for the next three quarters, or roughly $6.6–7.6 million per quarter. Management says the company will "approach adjusted EBITDA breakeven by the end of 2026" and cross to positive territory in the second half of 2027. Whether today's Q2 number makes that timeline credible or optimistic is the second test.

Volume growth is the one metric that actually proves demand

Revenue is useful, but analysis volume on the SOPHiA DDM platform is the leading indicator. Q1 set a record 108,000 analyses, up 16% year-over-year. FY2025 ended with 391,000 total analyses. The U.S. market grew 28% in Q1, APAC grew 31%, and EMEA revenue was up 30%.

The liquid biopsy application - MSK-ACCESS - is the wildcard. SOPHiA performed nearly 3,000 liquid biopsy analyses in Q1, up over 100% year-over-year, and has signed 100 customers across 30-plus countries to either MSK-ACCESS or MSK-IMPACT in less than two years. If Q2 shows liquid biopsy volume doubling again, that's evidence the new application isn't a press-release curiosity but a real growth vector. If it stalls, the story reverts to core genomics, which is growing steadily but not dramatically.

Net dollar retention tells you whether the base is sticky

Q1 net dollar retention (the percentage of revenue retained from existing customers, net of churn and expansion) rose to 117%, up from 103% a year ago. That means existing customers are spending more, not leaving. The full-year 2025 figure was 115%. The question is whether Q2 continues the expansion trend. A reading below 110% would signal the growth is coming purely from new logos rather than deepening relationships - a riskier, more expensive path to scale.

The CEO transition lands mid-earnings

Ross Muken, former president and COO, officially became CEO on July 1, succeeding co-founder Jurgi Camblong, who moves to executive chairman. This is Muken's first full quarter in the top job. He has a five-year history at the company, came from the CFO seat, and ran the commercial transformation that brought FY2025 revenue growth back to the high-teens. He's also the one who approved the targeted cost actions in April - modest headcount and operating spend reductions, which SOPHiA framed as "AI-driven productivity improvements" rather than a cut.

The earnings call will be the first time Muken sets his own tone. Watch for whether he leans into the breakeven timeline with specificity or keeps it at the guidance level.

Valuation context: what the market is paying for the bet

SOPH closed yesterday at $5.67 and is trading near $5.69 this morning. The stock is up approximately 82% over the past 12 months, from a 52-week low of $2.96 to a high of $6.77. It's currently sitting below that peak, which matters - the stock has room to move in either direction without breaking through fresh highs.

At roughly $390 million market cap and $92–94 million of guided revenue, the stock trades at about 4.1x forward sales. For context, unprofitable genomics and precision-medicine platforms have historically commanded 5–10x revenue when growth runs above 20%. SOPHiA is on the cheap end of that range, which means the market is pricing in execution risk, not just a lack of earnings. The P/B ratio of 8.5x is more telling of how much the stock is paying for intangible asset value rather than a hard equity floor.

The implied risk-reward hinges on whether Q2 confirms the operating leverage narrative. If revenue clears $23 million, adjusted EBITDA loss narrows below $9 million, and analysis volume growth stays above 15%, the case for continued upside from here is intact. If any of those three metrics deteriorates materially, the current price is more "cheap for a reason" than "mispriced bargain."

The barbell test

SOPHiA doesn't fit the dividend sleeve or the cash-flow-durability sleeve. It belongs in the quality-growth portion of a barbell, where it plays the role of a platform company approaching profitability. If you hold it, the counterweight should be something with yield or proven cash generation - the name hedges growth execution risk against actual cash return. When the Q2 number disappoints, the barbell structure absorbs the shock. When it delivers, the growth side does the heavy lifting.

The 6-K is just the container. The Q2 numbers inside it decide whether SOPHiA's turnaround is a trend or a timeline management exercise. We'll know after the bell rings.